Increased survival for metastatic prostate cancer with chemotherapy, hormone therapy together
The independent Data and Safety Monitoring Committee overseeing the trial recommended to the National Cancer Institute (NCI), part of NIH, that the study results be made public because a recent planned interim analysis showed prolongation in overall survival. Full details from this early analysis will be presented at a scientific meeting in 2014 and in a peer-reviewed publication. The study enrolled 790 men with metastatic prostate cancer between July 2006 and November 2012 in a trial known as E3805. …